Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hydroxyurea (hydroxycarbamide) for sickle cell disease.

Sarah J Nevitt1, Ashley P Jones1, Jo Howard2

  • 1Department of Biostatistics, University of Liverpool, Block F, Waterhouse Building, 1-5 Brownlow Hill, Liverpool, UK, L69 3GL.

The Cochrane Database of Systematic Reviews
|April 21, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endotracheal surfactant for infants with life-threatening bronchiolitis (BESS): a randomised, blinded, sham-controlled, phase 2 trial.

The Lancet. Respiratory medicine·2026
Same author

Re-anchoring the Value of Innovative Therapies in NICE Decision Making When Comparators are Cost Ineffective: A Case Study of Late-Onset Pompe Disease.

PharmacoEconomics·2025
Same author

Service delivery, behavioural, and self-management interventions for children with epilepsy.

The Cochrane database of systematic reviews·2025
Same author

Prognostic factors predicting an unprovoked seizure recurrence in children and adults following a first unprovoked seizure.

The Cochrane database of systematic reviews·2025
Same author

Service delivery, behavioural, and self-management interventions for adults with epilepsy.

The Cochrane database of systematic reviews·2025
Same author

Methotrexate and ciclosporin both reduce levels of circulating interleukin (IL)-4 and IL-13 expressing CD4+ memory T cells in childhood atopic dermatitis.

Clinical and experimental dermatology·2025
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Hydroxyurea (hydroxycarbamide) effectively reduces pain crises and acute complications in sickle cell disease (SCD) patients with HbSS or HbSβºthal genotypes. However, more research is needed on long-term benefits, risks, and effects in HbSC genotypes.

Area of Science:

  • Hematology
  • Pharmacology
  • Genetics

Background:

  • Sickle cell disease (SCD) is a prevalent inherited blood disorder causing significant morbidity and reduced lifespan.
  • Hydroxyurea (hydroxycarbamide) is an oral chemotherapeutic agent that can alleviate SCD symptoms by increasing fetal hemoglobin levels.
  • This review is an updated analysis of previous findings on hydroxyurea therapy for SCD.

Purpose of the Study:

  • To evaluate the therapeutic effects of hydroxyurea in individuals diagnosed with sickle cell disease (SCD) across all genotypes and age groups.
  • To compare hydroxyurea treatment against placebo, standard care, or alternative interventions.

Main Methods:

  • Searched multiple databases and trial registries for randomized and quasi-randomized controlled trials of hydroxyurea in SCD patients.

Related Experiment Videos

  • Included trials were of at least one month duration and involved comparisons with placebo, standard therapy, or other interventions.
  • Authors independently assessed study eligibility, extracted data, and evaluated the risk of bias.

    • Main Results:

    • Hydroxyurea significantly improved pain crisis frequency, reduced hospital admissions, and decreased acute chest syndrome occurrences in HbSS and HbSβºthal genotypes.
    • Hydroxyurea therapy also led to increased fetal hemoglobin and neutrophil counts but showed no consistent differences in quality of life or adverse events.
    • Limited evidence suggests potential benefits in stroke prevention but also indicates more infections and acute chest syndrome in combined hydroxyurea/phlebotomy groups compared to transfusion/chelation.

    Conclusions:

    • Hydroxyurea demonstrates efficacy in reducing acute complications and pain episodes for SCD patients with HbSS or HbSβºthal genotypes.
    • It may help prevent neurological events in individuals at risk of stroke by maintaining specific blood flow velocities.
    • Further research is required to establish long-term benefits, optimal dosing, and risks, especially concerning fertility and effects on HbSC genotypes.